Angiotensin Converting Enzyme II Inhibitor

<strong>Angiotensin Converting Enzyme II Inhibitor</strong>_x000D_ <strong>Catalog number:</strong> B2010520_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 2 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 428.31 g/mol_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> molecular tool for various ACE2-related research studies_x000D_ <strong>Storage:</strong> 2-8°C_x000D_ <strong>Keywords:</strong> (S, S)-2-(1-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid, 2( S)-(1( S)-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid, ACE2 Inhibitor_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, Liu FF, Zhang K, Zhang C._x000D_ Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets._x000D_ Nat Rev Cardiol. 2014 Jul;11(7):413-26._x000D_ _x000D_ 2: Zheng H, Cao JJ. Angiotensin-Converting Enzyme Gene Polymorphism and Severe_x000D_ Lung Injury in Patients with Coronavirus Disease 2019. Am J Pathol. 2020_x000D_ Oct;190(10):2013-2017._x000D_ _x000D_ 3: Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and_x000D_ RAS inhibitors-lessons from available evidence and insights into COVID-19._x000D_ Hypertens Res. 2020 Jul;43(7):648-654._x000D_ _x000D_ 4: Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human_x000D_ homolog of angiotensin-converting enzyme. Cloning and functional expression as a_x000D_ captopril-insensitive carboxypeptidase. J Biol Chem. 2000 Oct_x000D_ 27;275(43):33238-43._x000D_ _x000D_ 5: Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus Disease 2019_x000D_ (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor_x000D_ Blockers Have a Biphasic Effect? J Am Heart Assoc. 2020 Apr 7;9(7):e016509._x000D_ _x000D_ 6: Natesh R, Schwager SL, Sturrock ED, Acharya KR. Crystal structure of the_x000D_ human angiotensin-converting enzyme-lisinopril complex. Nature. 2003 Jan_x000D_ 30;421(6922):551-4._x000D_ _x000D_ 7: Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-_x000D_ inhibitors and ARBs in COVID-19 patients. Elife. 2020 Apr 6;9:e57278._x000D_ _x000D_ 8: Pan X, Shao Y, Wu F, Wang Y, Xiong R, Zheng J, Tian H, Wang B, Wang Y, Zhang_x000D_ Y, Han Z, Qu A, Xu H, Lu A, Yang T, Li X, Xu A, Du J, Lin Z. FGF21 Prevents_x000D_ Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of_x000D_ ACE2/Angiotensin-(1-7) Axis in Mice. Cell Metab. 2018 Jun 5;27(6):1323-1337.e5._x000D_ _x000D_ 9: Simões e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2,_x000D_ angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J_x000D_ Pharmacol. 2013 Jun;169(3):477-92._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32804730/">_x000D_ 10: Deng JL, Jiang YQ, Guo YK, Li HL. Patients taking angiotensin-converting_x000D_ enzyme inhibitors/angiotensin II type I receptor blockers: higher risks of_x000D_ severe acute respiratory syndrome coronavirus 2 infection but milder clinical_x000D_ manifestations? Chin Med J (Engl). 2020 Nov 20;133(22):2650-2652.</a>_x000D_ _x000D_ <strong>Products Related to Angiotensin Converting Enzyme II Inhibitor</strong> <a href="https://moleculardepot.com/product-category/SARS-CoV-2/">: SARS-CoV-2</a>